Source - SMW
Summit Therapeutics has announced that the Company presented new preclinical data on ridinilazole were at ASM Microbe 2017, which was held in New Orleans, US from 1-5 June 2017.

"These positive preclinical data presented at ASM Microbe highlight the potency of ridinilazole against a wide range of C. difficile clinical isolates from patients with CDI," commented Dr David Roblin, President of Research and Development of Summit.

"Combining potency and selectivity, ridinilazole has shown positive results in clinical trials that support its potential to treat patients with CDI and reduce the rate of recurrent disease. It is thought that the preservation and restoration of the patient microbiome is important in reducing recurrence and ridinilazole's narrow spectrum is designed to achieve this. We believe ridinilazole has the potential to be a novel, and urgently needed, front-line treatment option for this serious disease."


 
At 1:18pm: (LON:SUMM) Summit Therapeutics PLC share price was +7.5p at 182.5p